GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Invivyd Inc (NAS:IVVD) » Definitions » EV-to-EBIT

Invivyd (Invivyd) EV-to-EBIT : -0.49 (As of May. 17, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Invivyd EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Invivyd's Enterprise Value is $104.70 Mil. Invivyd's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 was $-215.63 Mil. Therefore, Invivyd's EV-to-EBIT for today is -0.49.

The historical rank and industry rank for Invivyd's EV-to-EBIT or its related term are showing as below:

IVVD' s EV-to-EBIT Range Over the Past 10 Years
Min: -223.63   Med: 0   Max: 89.46
Current: -0.49

During the past 4 years, the highest EV-to-EBIT of Invivyd was 89.46. The lowest was -223.63. And the median was 0.00.

IVVD's EV-to-EBIT is ranked worse than
100% of 431 companies
in the Biotechnology industry
Industry Median: 10 vs IVVD: -0.49

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Invivyd's Enterprise Value for the quarter that ended in Mar. 2024 was $341.71 Mil. Invivyd's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 was $-215.63 Mil. Invivyd's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was -63.10%.


Invivyd EV-to-EBIT Historical Data

The historical data trend for Invivyd's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Invivyd EV-to-EBIT Chart

Invivyd Annual Data
Trend Dec20 Dec21 Dec22 Dec23
EV-to-EBIT
- -0.97 0.90 -1.13

Invivyd Quarterly Data
Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EV-to-EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.21 1.09 0.47 -1.13 -1.58

Competitive Comparison of Invivyd's EV-to-EBIT

For the Biotechnology subindustry, Invivyd's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Invivyd's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Invivyd's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Invivyd's EV-to-EBIT falls into.



Invivyd EV-to-EBIT Calculation

Invivyd's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=104.695/-215.626
=-0.49

Invivyd's current Enterprise Value is $104.70 Mil.
Invivyd's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-215.63 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Invivyd  (NAS:IVVD) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Invivyd's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Mar. 2024 ) =EBIT / Enterprise Value (Q: Mar. 2024 )
=-215.626/341.71224
=-63.10 %

Invivyd's Enterprise Value for the quarter that ended in Mar. 2024 was $341.71 Mil.
Invivyd's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-215.63 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Invivyd EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Invivyd's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Invivyd (Invivyd) Business Description

Traded in Other Exchanges
N/A
Address
1601 Trapelo Road, Suite 178, Waltham, MA, USA, 02451
Invivyd Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The company is developing antibodies to transcend the limits of naturally occurring immunity and provide superior protection from viral diseases, beginning with COVID-19. The company's product candidates are; ADG20 developed for the treatment and prevention of coronavirus disease, and VYD222, a monoclonal antibody candidate engineered, optimizing for potency and breadth of coverage, as well as providing a higher probability of retaining its utility for a longer duration in an evolving viral landscape.
Executives
Adimab, Llc 10 percent owner, other: See Remarks 7 LUCENT DRIVE, LEBANON NH 03766
William E. Duke officer: Chief Financial Officer C/O VALERITAS, INC., 750 ROUTE 202 SOUTH, SUITE 600, BRIDGEWATER NJ 08807
Sara Cotter director 1735 MARKET STREET, FLOOR 23, PHILADELPHIA PA 19103
Allen Robert D. Iii officer: Chief Scientific Officer 1601 TRAPELO ROAD, SUITE 178, WALTHAM MA 02451
Stacy Price officer: Chief Tech. and Manuf. Officer 1601 TRAPELO ROAD, SUITE 178, WALTHAM MA 02451
Jeremy Gowler officer: COO & CCO 1601 TRAPELO ROAD, SUITE 178, WALTHAM MA 02451
Rebecca Dabora officer: Chief Tech and Manuf Officer 303 WYMAN STREET, SUITE 300, WALTHAM MA 02451
Peter Schmidt officer: Chief Medical Officer 1601 TRAPELO ROAD, SUITE 178, WALTHAM MA 02451
Jill Andersen officer: Chief Legal Officer, Secretary 303 WYMAN STREET, SUITE 300, WALTHAM MA 02451
Christine Lindenboom director 1601 TRAPELO ROAD, SUITE 178, WALTHAM MA 02451
Frederick W Driscoll officer: Interim CFO
David Hering director, officer: Chief Executive Officer 303 WYMAN STREET, SUITE 300, WALTHAM MA 02451
Marc Elia director, other: See Remarks C/O SQZ BIOTECHNOLOGIES COMPANY, 200 ARSENAL YARDS BOULEVARD, SUITE 210, WATERTOWN MA 02472
M28 Capital Management Lp other: See Remarks 700 CANAL STREET, 2ND FLOOR, STAMFORD CT 06902
Clive Meanwell director, 10 percent owner THE MEDICINES CO, 8 SYLVAN WAY, PARSIPPANY NJ 07054

Invivyd (Invivyd) Headlines

From GuruFocus